Literature DB >> 16965419

A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment.

J Berth-Jones1, K Grotzinger, C Rainville, B Pham, J Huang, S Daly, M Herdman, P Firth, K Hotchkiss.   

Abstract

BACKGROUND: There is a lack of consensus as to the best way of monitoring psoriasis severity in clinical trials. The Psoriasis Area and Severity Index (PASI) is the most frequently used system and the Physician's Global Assessment (PGA) is also often used. However, both instruments have some drawbacks and neither has been fully evaluated in terms of 'validity' and 'reliability' as a psoriasis rating scale. The Lattice System Physician's Global Assessment (LS-PGA) scale has recently been developed to address some disadvantages of the PASI and PGA.
OBJECTIVES: To evaluate the inter-rater and intrarater reliability of the PASI, PGA and LS-PGA.
METHODS: On the day before the study, 14 dermatologists (raters), with varied experience of assessing psoriasis, received detailed training (2.5 h) on use of the scales. On the study day, each rater evaluated 16 adults with chronic plaque psoriasis in the morning and again in the afternoon. Raters were randomly assigned to assess subjects using the scales in a specific sequence, either PGA, LS-PGA, PASI or PGA, PASI, LS-PGA. Each rater used one sequence in the morning and the other in the afternoon. The primary endpoint was the inter-rater and intrarater reliability as determined by intraclass correlation coefficients (ICCs).
RESULTS: All three scales demonstrated 'substantial' (a priori defined as ICC > 80%) intrarater reliability. The inter-rater reliability for each of the PASI and LS-PGA was also 'substantial' and for the PGA was 'moderate' (ICC 75%).
CONCLUSIONS: Each one of the three scales provided reproducible psoriasis severity assessments. In terms of both intrarater and inter-rater reliability values, the three scales can be ranked from highest to lowest as follows: PASI, LS-PGA and PGA.

Entities:  

Mesh:

Year:  2006        PMID: 16965419     DOI: 10.1111/j.1365-2133.2006.07389.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  22 in total

1.  Design of an Algorithm for Automated, Computer-Guided PASI Measurements by Digital Image Analysis.

Authors:  Christine Fink; Tobias Fuchs; Alexander Enk; Holger A Haenssle
Journal:  J Med Syst       Date:  2018-11-03       Impact factor: 4.460

2.  Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity.

Authors:  Baris Yilmazer; Tayfun Sahin; Berrin Öztaş Unlu; Hale Maral Kir; Ayse Cefle
Journal:  Rheumatol Int       Date:  2015-02-11       Impact factor: 2.631

3.  Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

Authors:  Silje Watterdal Syversen; Guro Løvik Goll; Kristin Kaasen Jørgensen; Øystein Sandanger; Joseph Sexton; Inge Christoffer Olsen; Johanna Elin Gehin; David John Warren; Marthe Kirkesæther Brun; Rolf Anton Klaasen; Lars Normann Karlsen; Geir Noraberg; Camilla Zettel; Maud Kristine Aga Ljoså; Anne Julsrud Haugen; Rune Johan Njålla; Trude Jannecke Bruun; Kathrine Aglen Seeberg; Brigitte Michelsen; Eldri Kveine Strand; Svanaug Skorpe; Ingrid Marianne Blomgren; Yngvill Hovde Bragnes; Christian Kvikne Dotterud; Turid Thune; Carl Magnus Ystrøm; Roald Torp; Pawel Mielnik; Cato Mørk; Tore K Kvien; Jørgen Jahnsen; Nils Bolstad; Espen A Haavardsholm
Journal:  JAMA       Date:  2021-05-04       Impact factor: 56.272

4.  Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.

Authors:  Lauren A George; Akash Gadani; Raymond K Cross; Guruprasad Jambaulikar; Leyla J Ghazi
Journal:  Dig Dis Sci       Date:  2015-06-27       Impact factor: 3.199

5.  Effect of new Pulian Ointment () in treating psoriasis of blood-heat syndrome: A randomized controlled trial.

Authors:  Ning Zhou; Yan-ping Bai; Xiao-hong Man; Yun-bi Zhang; Yu-hong Kong; Hai Ju; Ming Chang
Journal:  Chin J Integr Med       Date:  2010-01-18       Impact factor: 1.978

6.  Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-11-01

7.  Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity.

Authors:  J C Cappelleri; A G Bushmakin; J Harness; C Mamolo
Journal:  Qual Life Res       Date:  2013-03-09       Impact factor: 4.147

8.  Immunohistochemical Expression of Caspase-3 in Psoriasis.

Authors:  Shaimaa M M Bebars; Dalia Rifaat Al-Sharaky; Mohammed A Gaber; Dina Ragab Afify
Journal:  J Clin Diagn Res       Date:  2017-07-01

Review 9.  Measuring Outcomes in Psoriatic Arthritis.

Authors:  Alexis Ogdie; Laura C Coates; Philip Mease
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-10       Impact factor: 4.794

10.  Thermal waters as cosmeceuticals: La Roche-Posay thermal spring water example.

Authors:  Sophie Seite
Journal:  Clin Cosmet Investig Dermatol       Date:  2013-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.